Date: 14 Oct 2022
SINGAPORE, July 29, 2022/ -- HistoIndex, a global leading artificial intelligence digital pathology (AI-DP) provider, announced that its AI-based qFibrosis®, qSteatosis® and qBallooning® algorithms delivered sensitivity and granularity on a...Read More
Date: 18 May 2022
HistoIndex, a global leading artificial intelligence digital pathology (AI-DP) provider, is very pleased to announce the appointment of Dr. David John Jeans CBE as Non-Executive Director of the company's Board.Read More
Date: 09 Mar 2022
HistoIndex, a global leading artificial intelligence digital pathology (AI-DP) provider, has joined forces with Key Opinion Leaders (KOLs) worldwide in the Nonalcoholic Steatohepatitis (NASH) field to study and validate the reliability of quantifying hepatocyte (liver cell) ballooning injury with its AI-based Second Harmonic Generation/Two-photon Excitation Fluorescence (SHG/TPEF) stain-free imaging and novel qBallooning2 machine learning algorithm.
The study highlights the potential of training AI digital pathology with a guided 'Concordance Atlas' to quantify ballooned hepatocytes in a reliable and reproducible manner. The Atlas would then be used to develop and train machine learning AI algorithms in detecting and quantifying the degree of hepatocyte ballooning with higher consistency, sensitivity, and specificity using SHG/TPEF stain-free technology. Findings from this study have recently been published in the Journal of Hepatology.
Date: 01 Nov 2021
HistoIndex announces the appointment of Mr. Robert Davidson as Chief Financial Officer. Robert is a chartered accountant and joins the HistoIndex senior management with more than 20 years of experience in strategic finance, operations management and corporate governance including previous board-level directorship.
Says Robert on his new beginning at HistoIndex, “It is an honour to be appointed as CFO, as I am inspired by the dedication shown by the exceptional team at HistoIndex in making a difference in the drug development and clinical diagnostics space for better patient outcomes. I believe that my experience along with my growing knowledge of the company’s proprietary technology and business model makes me well aligned with the vision of this company. I am eager to work with Gideon and the HistoIndex team in achieving great success.”
Date: 20 Oct 2021
HistoIndex, a global leading artificial intelligence digital pathology (AI-DP) provider, has announced a collaboration with Galecto, Inc., a biotechnology company focused on the development of novel treatments for fibrosis and cancer.
This collaboration expands HistoIndex's portfolio of fibrosis assessment outside of Nonalcoholic Steatohepatitis (NASH) and other liver diseases. The proprietary stain-free imaging technology, incorporated by Second Harmonic Generation (SHG) along with AI-based algorithms, will be utilized to analyze and quantify collagen-associated parameters as part of Galecto's Phase 2a trial for its oral LOXL2 inhibitor GB2064 in myelofibrosis.Read More
Date: 18 Aug 2021
HistoIndex has announced an agreement with clinical-stage biotechnology company Sagimet Biosciences, where its integrated suite of stain-free imaging with AI-based fully quantitative and zonal analysis of fibrosis will play a role in Sagimet’s Nonalcoholic Steatohepatitis (NASH) Phase 2b multi-center, double-blind, randomized placebo-controlled trial (FASCINATE-2) as both secondary and exploratory efficacy endpoints.
The integrated AI stain-free platform, which comprises the Genesis®200 Second Harmonic Generation (SHG) imaging system and image analysis algorithms, will assess approximately 330 paired patient biopsies for secondary efficacy endpoints.Read More
Date: 25 Jun 2021
HistoIndex's Second Harmonic Generation (SHG) stain-free digital pathology platform has shown marked reduction in liver fibrosis (overall, reduction in perisinusoidal fibrosis, as well as regression of fibrous septa) from baseline to end-of-treatment at 48 weeks, in patients with NASH participating in a Phase 2 FLIGHT-FXR study. The data from the analysis further illustrates the significance of the AI-based digital pathology platform in revealing fibrosis regression in patients treated with Tropifexor (TXR) and its relation to steatosis (liver fat) reduction.
The results of this study were presented at EASL's International Liver Congress™ 2021 (ILC 2021) entitled, "Digital Pathology with Artificial Intelligence Analyses Reveal New Dynamics of Treatment-induced Fibrosis Regression in Nonalcoholic Steatohepatitis".Read More
Date: 25 Jan 2021
HistoIndex's stain-free AI digital pathology platform, incorporating Second Harmonic Generation (SHG), holds promise as a quantitative tool in the assessment of morphological and architectural changes in collagen fibers within the tumor-stromal microenvironment in patients with TNBC.
This will allow clinicians to better interpret the role of collagen remodeling in tumor progression and its prognostic value. On a larger scale, the tool may greatly aid existing and future TNBC studies that are currently exploring new therapies for targeted treatments.Read More
Date: 15 Dec 2020
HistoIndex has joined INTErPRET-NAFLD, an international liver R&D collaboration aimed at developing an integrated precision AI diagnostics tool for High-Risk Nonalcoholic Fatty Liver Disease (NAFLD).
Led by the University of Edinburgh, the multi-centre collaboration was recently awarded with a S$1.2M (750,000 Euros) innovative research grant, which will support the collaborators' mutual goal of developing and validating a tool that can accurately identify NAFLD patients who are at a higher risk of progressing to NASH, which can lead to adverse outcomes such as the irreversible cirrhosis, liver cancer and premature death.
Date: 18 Nov 2020
HistoIndex's Second Harmonic Generation (SHG) stain-free digital pathology platform for the automated quantitative assessment of histological features has shown promising analyses that indicate post-treatment improvements in fibrosis. This was stated at an Oral Presentation entitled, "Safety and Efficacy of Tropifexor in Patients with Fibrotic Nonalcoholic Steatohepatitis: 48-week Results from Part C of the Phase 2 FLIGHT-FXR Study", during AASLD's The Liver Meeting Digital Experience™ 2020.
HistoIndex's quantitative analyses revealed novel aspects of improvement of NASH fibrosis beyond the conventional scoring of liver biopsies for Tropifexor-treated patients. In addition, zonal quantification of fibrosis changes showed a fibrosis improvement in the intermediary area of Zone 2 for Tropifexor-treated patients compared with placebo.Read More